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RT-PCR ANALYSIS OF TOPBP1 GENE EXPRESSION IN HEREDITARY 
BREAST CANCER 
 
 
Abstract: Hereditary predisposition to breast cancer determined in large part by loss 
of function mutations in one of two genes BRCA1 and BRCA2. Besides BRCA1 and 
BRCA2 other genes are also likely to be involved in hereditary predisposition to 
breast cancer. TopBP1 protein is involved in DNA replication, DNA damage 
checkpoint response and transcriptional regulation. Expression of TopBP1 gene at 
the mRNA level was analyzed by semiquantitative reverse transcription-polymerase 
chain reaction (RT-PCR) in 94 samples of hereditary breast cancer. Analysis of 
TopBP1 mRNA level showed that expression of TopBP1 is significantly 
downregulated in poorly differentiated breast cancer (grade III according Bloom-
Richardson system (P<0.05). 
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1. INTRODUCTION 
 Hereditary breast and ovarian cancer syndrome is an inherited cancer 
susceptibility syndrome. The hallmarks of this syndrome are multiple family 
members with breast or/and ovarian cancer, the presence of both breast and ovarian 
cancer in a single individual, and early age of breast cancer onset (LU et al. 2009). 
DOI: 10.2478/v10107-009-0006-1 
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Breast and ovarian cancers are among the most common malignancies of women in 
Western countries. About 5 – 10% of the cases are considered familial, and 40 – 
50% of them can currently be explained by mutations in two main susceptibility 
genes, BRCA1 and BRCA2.  Of the remaining cases no more than 5% are caused by 
defects in other studied genes, such as TP53, PTEN, ATM and CHK2 (KARPPINEN et 
al. 2006; EASTON 1999). TopBP1 (topoisomerase IIβ binding protein 1) displays 
structural as well as functional similarities with BRCA1, and both proteins have 
been suggested to function partly in the same cellular processes (KARPPINEN et al. 
2006). Based on its biological significance KARPPINEN et al. (2006) suggested that 
TopBP1 is a plausible susceptibility gene for hereditary breast and/or ovarian 
cancer. Aberrant expression of TopBP1 may be involved in the deregulation of 
processes controlled by this protein and have pathological consequences. The aim of 
this study was to investigate the expression of TopBP1 at the mRNA level in 
hereditary breast cancer. 
 
2. MATERIALS AND METHODS 
2.1. Sample collection 
Samples of 94 hereditary breast cancers were obtained from patients (age 
range 28 – 67 years) undergoing surgery for breast neoplasms in Polish Mather’s 
Memorial Hospital, Poland. The inclusion criteria were: (1) at least one first-degree 
relative with breast cancer, regardless of age, or (2) breast cancer diagnosed below 
40 years of age. None of the patient received neoadjuvant endocrine therapy, 
chemotherapy and radiotherapy. The pathological evaluation report was obtained for 
each patient (Table 1). Immediately after resection, samples of breast cancer tissue 
were fixed in 10% neutral buffered formalin and embedded in paraffin blocks 
following standard histological protocols. For our studies tissue sections were cut 
from the blocks with a microtome blade, extra paraffin was removed, and tissue 
sections was placed in a 1.5-ml microcentrifuge tube.  
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Table 1. Characteristics of patients and tumor samples 
 
Characteristics Number of patients 
Age at diagnosis  
range 28 - 67 
mean ± SD 55.3 ± 8.5 
Type of cancer  
ductal carcinoma 79 
lobular carcinoma 13 
tubular carcinoma 2 
Tumor grade according to 
Bloom-Richardson system 
 
I 9 
II 64 
III 21 
Lymph node metastasis  
No 52 
Yes 42 
Menopausal status  
premenopausal 55 
postmenopausal 39 
ER status  
Negative 46 
Positive 48 
PR status  
Negative 42 
Positive 52 
 
2.2. Total RNA extraction and cDNA synthesis 
Xylene deparaffinization: Sections were deparaffinized by two rinses in 
xylene for 10 min at room temperature with shaking, followed by centrifugations at 
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room temperature for 5 min at 12,000g. After deparaffinization, we introduced a 
rehydratation step (rinsing in 100% ethanol, 85%, 70% ethanol, all prepared with 
DEPC treated dH2O, for 5 min). The tissue was collected by centrifugation at 
12,000g for 5 min. After the final wash, alcohol was aspirated and the tissue pellets 
were resuspended in 500 µl of digestion buffer (10 mM NaCl, 500 mM Tris-HCl, 
pH 8.0, 25 mM EDTA, 1% SDS) and 1 mg/ml proteinase K was added. Sections 
were incubated at 45°C overnight. Prior to RNA purification, in same samples we 
inactivated proteinase K at 97°C for 10 min. The digested samples were extracted 
using TRI Reagent (Sigma Aldrich, USA) according to manufacturer’s protocol. 
RNA was eluted in 20 µl RNase-free water, quantified by spectrophotometry at 260 
nm and stored at -20°C. RNA with a 260/280 nm ratio in range 1.8 – 2.0 was 
considered high quality. First-strand cDNA was synthesized from each RNA pool 
using PCR Kit ver. 3.0 (Takara Bio Inc. Japan) according to the manufacturer’s 
instructions. Briefly, 1 µg RNA was combined with 2.5 pmol of oligo dT-adapter 
primer, 4 µl of 25 mM MgCl2, 2 µl 10 x RNA PCR buffer, 2 µl of 10 mM dNTP 
mixture, 20 units of RNase inhibitor, 5 units of AMV Reverse Transcriptase XL, and 
RNase-free water to total volume of 20 µl. The reaction took place at 42°C for 30 
min, followed by 95°C for 5 min and 5°C for 5 min in a GeneAmp PCR System 
9700 (Perkin-Elmer Co, USA). cDNA was stored at -20°C. 
 
2.3. RT-PCR 
One microliters of cDNA sample was used as a substrate for PCR reaction in 
a 20 µl volume with 1 µM of forward and reverse primers, 0.2 mM of each dNTP, 
1.5 mM MgCl2, 2.0 µl 10 x PCR buffer (200 mM Tris-HCl, pH 8.4, 500 mM KCl) 
and 1 units Taq polymerase (Takara Bio Inc., Japan). Specific oligonucleotide 
primers for TopBP1 were as follows F: 5’GCTTCATCGCTCCTACCTTG3’, R: 
5’TTCCACCCACTAAATGCTCC3’. Glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) with primer sequences F: 5’GAAGGTGAAGGTCGGACTC3’, R: 
5’GAAGATGGTGATGGGATTTC 3’ was used as an endogenous control for the 
PCR amplifications. PCR reaction was carried out as follows: initial denaturation of 
4 min at 94°C) followed by 40 cycles of 1 min at 94°C, 30 s at 53°C for TopBP1 and 
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60°C for GAPDH and 30 s at 72°C, final extension step of 10 min at 72°C. Negative 
control and already amplified cDNA were included in all the PCR amplifications. 
The size of amplified fragments was 210 and 225 bp for TopBP1 and GAPDH, 
respectively. After amplification 10 µl of PCR products were combined with 2 µl 
gel loading buffer and the mixture was separated on a 8% polyacrylamide gel. The 
gel was silver stained. For qualitative and quantitative analysis of silver nitrate 
stained gels video densitometr (Biotec-Fischer, Germany) with the software program 
Gel-Pro® Analyzer 3.0 (Media Cybemetics, USA) was used. All RT-PCR reactions 
were repeated 2 times for each samples. The integrated optical density (IOD) of the 
bands in a digitalized picture was measured. TopBP1 gene expression was 
determined as the ratio of TopBP1 to GAPDH.  
 
2.4. Statistical analysis 
All data are presented as mean ± SEM. Because results obtained from RT-
PCR were not normally distributed (Kolmogorov-Smirnov test), therefore 
nonparametric Mann-Whitney U-test (for two categories) and the Kruskal-Wallis 
test with post hoc multiple comparisons (for three categories) were used. Statistical 
significance was designated at P<0.05. 
 
3. RESULTS 
The expression of TopBP1 in hereditary breast cancer was estimated at the 
mRNA level by semiquantitative RT-PCR analysis with GAPDH applied as a 
reference gene. Representative electropherogram of TopBP1 mRNA expression in 
hereditary breast cancer with GAPDH mRNA as standard is presented in Fig. 1. 
Expression of TopBP1 gene at the mRNA level was observed in 81 of 94 (86.2%) 
hereditary breast cancer samples. The comparison of transcript level of TopBP1 
gene with clinicopathological parameters of tumors is shown in Table 2, where ratio 
of integrated optical density TopBP1 to GAPDH representing the mean level of 
mRNA, are used for statistical analysis. Analysis of TopBP1 mRNA level showed 
significantly lower expression of TopBP1 in the poorly differentiated hereditary 
breast cancer (grade III according to Bloom-Richardson scale) in comparison with 
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moderately and well-differentiated cancer  (P<0.05). No statistically significant 
differences occured between TopBP1 mRNA level in grade I and II tumors (Fig. 2).  
 
 
 
Fig. 1. Representative electropherogram of TopBP1 mRNA expression in hereditary 
breast cancers with GAPDH mRNA as standard (M molecular weight markers).  
Amplification products were separated on the 8% polyacrylamide gel. T – TopBP1; 
G – GAPDH; M – molecular weight markers. 
 
 
Fig. 2. Expression of TopBP1 mRNA in hereditary breast cancers in relation to 
tumor grade. Asterisk indicates significant differences at P<0.05. 
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There were no significant associations between level of TopBP1 mRNA expression 
and other clinicopathological parameters, such as estrogen and progesterone receptor 
status, appearance of metastasis in the axillary lymph nodes and type of cancer. 
 
Table 2. Comparison of the transcript levels of TopBP1 gene with clinicopatho-
logical parameters of the tumors 
 
Clinicopathological 
features (N) 
Semiquantitative 
RT-PCR 
(IODTopBP1/GAPDH) 
P 
Type of cancer   
ductal carcinoma (79) 0.14 ± 0.01  
lobular carcinoma (13) 0.12 ± 0.02 0.45 
Tumor grade   
I (9) 0.13 ± 0.03  
II (64) 0.11 ± 0.01  
III (21) 0.07 ± 0.02 0.60 
Lymph node status   
No (52) 0.13 ± 0.01  
Yes (42) 0.11 ± 0.01 0.67 
ER status   
Negative (46) 0.12 ± 0.01  
Positive (48) 0.10 ± 0.01 0.64 
PR status   
Negative (42) 0.11 ± 0.01  
Positive (52) 0.13 ± 0.01 0.20 
 
4. DISCUSSION 
TopBP1 protein plays a key role in various aspects of DNA metabolism. It is 
required for the initiation of DNA replication, the maintenance of DNA replication 
forks when replication is stalled and for DNA damage signaling and checkpoints 
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(JEON et al. 2007; KIM et al., 2005; KUMAGAI et al. 2006; LIU et al 2006; 
MORISHIMA et al. 2007; SCHMIDT et al 2008; YAMMANE et al. 2003). TopBP1 is 
also involved in the process of mitosis in somatic cells and during meiotic 
recombination in germ cells (PERERA et al. 2004; REINI et al. 2004). Most of 
TopBP1 does not colocalize at site of ongoing DNA replication in irradiated cells 
but is relocalized to stalled replication forks upon DNA damage. The involvement of 
TopBP1 in DNA replication is supported by the demonstration that incubation of an 
antibody against the sixth BRCT motif of TopBP1 inhibits replicative DNA 
synthesis in a in vitro HeLa cell nucleus replication assay (KIM et al. 2004; 
MAKINEMI et al. 2001). TopBP1 can interact with human polymerase ε, checkpoint 
protein Rad9, Miz-1, E2F1, human papilliomavirus type 16 (HPV16) 
transcription/replication factor E2 (BONER et al. 2002; DONALDSON et al. 2007; 
DELACROIX et al. 2007; HEROLD et al. 2002; LIU et al. 2003, 2004, 2006; 
MAKINIEMI et al. 2001) . TopBP1 also participates in ATR activation in ATRIP-
dependent manner (BURROWS, ELLEDGE 2008; CIMPRICH, CORTEZ 2008; KUMAGAI 
et al. 2006; LEE et al. 2007). In addition to control DNA replication, TopBP1 is also 
required for cell survival. Inhibition of TopBP1 expression induces apoptosis. 
TopBP1 is involved in several important aspects of regulation cell growth (LIU et al. 
2003; YAMANE et al. 2002). The aim of this study was investigate the transcript 
level of TopBP1 gene. Analysis of TopBP1 expression shown that tumor progression 
is accompanied by a decrease of TopBP1 mRNA level. Expression of TopBP1 is 
regulated by Rb/E2F1 and is induced when cells enter into S phase (LIU et al. 2004, 
2009; YOSHIDA, INOUE 2004). Therefore, disruption of Rb/E2F1 pathway can lead to 
overexpression of TopBP1 protein in breast cancers. In the other hand, TopBP1 
regulates activity of E2F1 and overexpression of TopBP1 suppressed E2F1 
transcriptional activity (LIU et al. 2003, 2004). Thus, decreased transcriptional 
activity of E2F1 by TopBP1 can repress the expression of E2F1 target genes, 
including TopBP1. In the other hand, downregulation of TopBP1 mRNA expression 
may be caused by aberration expression of E2F1. Many studies have found that 
expression of E2F1 protein in breast cancer tended to decreased as the grade 
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increase (HO et al. 2001; KWON et al. 2009). However, regulation of TopBP1 
expression will need to be studied. 
 
Acknowledgements 
This work was supported by the grant of Integrated Operational Program for 
Regional Development, ZPORR (grant no. 10/S-UŁ/2009). The project was also co-
founded by the European Union under the European Social Fund, POKL “Human – 
Best Investment!”. 
  
5. REFERENCES 
BONER, W., TAYLOR,  E.R., TSIRIMONAKI, E., YAMANE, K., CAMPO, M.S., 
MORGAN, I.M. 2002. A functional interaction between the human papillomavirus 
16 transcription/replication factor E2 and the DNA damage response protein 
TopBP1. J. Biol. Chem.  277: 22297–22303. 
BURROWS, A.E., ELLEDGE, S. 2008. How ATR turns on: TopBP1 goes on ATRIP 
with ATR. Genes Dev. 22: 1416–1421. 
CIMPRICH, K.A., CORTEZ, D. 2008. ATR: an essential regulator of genome integrity. 
Nature Rev. Mol. Cell Biol. 9: 616–627. 
DELACROIX, S., WAGNER,  J.M., KOBAYASHI,  M., YAMAMOTO, K.I., KARNITZ, L.M. 
2007. The Rad9-Hus1-Rad1 (9-1-1) clamp activates checkpoint signaling via 
TopBP1. Genes Dev. 21: 1472–1477. 
DONALDSON,  M.M., BONER, W., MORGAN, I.M. 2007. TopBP1 regulates human 
papillomavirus type 16 E2 interaction with chromatin. J. Virol. 81: 4338–4342. 
EASTON, D.F. 1999. How many more breast cancer predisposition genes are there? 
Breast Cancer Res. 1: 14–17. 
HEROLD, S., WANZEL, M., BEUGER, V., FROHME, C., BEUL, D., HILLUKKALA, T., 
SYVAOJA, J., SALUZ, H.P., HAENEL, F., EILERS, M. 2002. Negative regulation of 
the mammalian UV response by Myc through association with Miz-1. Mol. Cell 
10: 509–521. 
Expression of TopBP1 58
HO, G.H., CALVANO, J.E., BISOGNA, M., VAN ZEE, K.J. 2001. Expression of E2F-1 
and E2F-4 is reduced in primary and metastatic breast carcinomas. Breast Cancer 
Res. Treat. 69: 115–122. 
JEON, Y., LEE, K.Y., KO, M.J., LEE, Y.S., KANG, S., HWANG. D.S. 2007. Human 
TopBP1 participates in cyclinE/CDK2 activation and preinitiation complex 
assembly during G1/S transition. J. Biol. Chem. 282: 14882–14890. 
KARPPINEN, S.M., ERKKO, H., REINI, K., POSPIECH, H., HEIKKINEN, K., RAPAKKO, 
K., SYVAOJA, J.E., WINQVIST, R. 2006. Identification of a common 
polymorphism in the TopBP1 gene associated with hereditary susceptibility to 
breast and ovarian cancer. Eur. J. Cancer.  42: 2647–2652. 
KIM, J.E., MCAVOY, S.A., SMITH, D.I., CHEN, J. 2005. Human TopBP1 ensures 
genome integrity during normal S phase. Mol. Cel. Biol. 25: 10907–10915. 
KUMAGAI, A., LEE, J., YOO, H.Y., DUNPHY, W.G. 2006. TopBP1 activates the ATR-
ATRIP complex. Cell 124: 943–955. 
KWON, M.J., NAM, E.S., CHO, S.J., PARK, H.R., SHIN, H.S., PARK, J.H., PARK, C.H., 
LEE, W.J. 2009. E2F1 expression predicts outcome in Korean women who 
undergo surgery for breast cancer. Ann. Surg. Oncol. 17: 564–71. 
LEE, J., KUMAGAI, A., DUNPHY, W.G. 2007. The Rad9-Hus1-Rad-1 checkpoint 
clamp regulates interaction of TopBP1 with ATR. J. Biol. Chem. 282: 28036–
28044. 
LIU, K., LIN, F.T., RUPPERT,  J.M., LIN, W.C. 2003. Regulation of E2F1 by BRCT 
domain-containing protein TopBP1. Mol. Cell. Biol. 23: 3287–3304. 
LIU, K., LUO, Y., LIN, F.T., LIN, W.C. 2004. TopBP1 recruits BRG1/BRM to 
repress E2F1-induced apoptosis, a novel pRb-independent and E2F1-specific 
control for cell survival. Genes Dev. 21: 1472–1477. 
LIU, K., PAIK, J.C., WANG, B., LIN, F.T., LIN. W.C. 2006 Regulation of TopBP1 
oligomerization by Akt/PKB for cell survival. EMBO J. 25: 4795–4807. 
LIU, K., BELLAM,  N., LIN, H.Y., WANG, B., STOCKARD, C.R., GEIZZLE, W.E., LIN, 
W.C. 2009. Regulation of p53 by TopBP1: a potential mechanism for p53 
inactivation in cancer. Mol. Cell. Biol. 29: 2673–2693. 
 
E. FORMA, M. BERNACIAK, H. ROMANOWICZ-MAKOWSKA & M. BRYŚ 59
LU, K., KAUFF, N., POWELL, B., CHEN, L.M., CASS, I., LANCASTER, J. 2009. 
Hereditary breast and ovarian syndrome, ACOG Practice Bull. Gynecol. Oncol. 
113: 6–11. 
MAKINIEMI, M., HILLUKKALA, T., TUUSA, J., REINI, K., VAARA, M., HUANG, D., 
POSPIECH, H., MAJURI, I., WESTERLING, T., MÄKELÄ, T.P., SYVÄOJA, J.E. 2001.  
BRCT domain-containing protein TopBP1 functions in DNA replication and 
damage response. J. Biol. Chem. 276: 30099–30406. 
MORISHIMA, K.I., SAKAMOTO, S., KOBAYASHI, J., IZUMI, H., SUDA, T., 
MATSUMOTO, Y., TAUCHI, H., IDE, H., KOMATSU, K., MATSUURA, S. 2007. 
TopBP1 associates with NBS1 and is involved in homologous recombination 
repair, Biochem. Biophys. Res. Commun. 362: 872–879.  
PERERA, D., PEREZ-HIDALGO, L., MOENS, P.B., REINI, K., LAKIN, N., SYVÄOJA, 
J.E., SAN-SEGUNDO, P.A., FREIRE, R. 2004. TopBp1 and ATR colocalization at 
meiotic chromosomes: role of TopBP1/Cut5 in the meiotic recombination 
checkpoint, Mol. Biol. Cell 15: 1568–1579. 
REINI, K., UITTO, L., PERERA, D., MOENS, P.B., FREIRE, R., SYVÄOJA, J.E. 2004. 
TopBP1 localises to centrosomes in mitosis and chromosome cores in meiosis, 
Chromosoma 112: 323–330. 
SCHMIDT, U., WOLLMANN, Y., FRANKE, C., GROSSE, F., SALUZ, H.P., HANEL, F. 
2008. Characterization of the interaction between the human DNA topoisomerase 
IIβ-binding protein 1 (TopBP1) and the cell division cycle protein 45 (Cdc45). 
Biochem. J. 409: 169–177. 
YAMANE, K., CHEN, J., KINSELLA, T.J. 2003. Both DNA  topoisomerase II-binding 
protein 1 and BRCA1 regulate the G2-M cell cycle checkpoint. Cancer Res. 63: 
3049–3053. 
YAMANE, K., WU, X., CHEN, J. 2002.  A DNA damage-regulated BRCT-containing 
protein, TopBP1, is required for cell survival.  Mol. Cell. Biol. 22: 555–566. 
YOSHIDA, K., INOUE, I. 2004.  Expression of MCM10 and TopBP1 is regulated by 
cell proliferation and UV irradiation via the E2F1 transcription factor. Oncogene 
23: 6250–6260.  
